Proton NMR-Based Metabolite Analyses of Archived Serial Paired Serum and Urine Samples from Myeloma Patients at Different Stages of Disease Activity Identifies Acetylcarnitine as a Novel Marker of Active Disease

Alessia Lodi, Stefano Tiziani, Farhat L Khanim, Ulrich L Günther, Mark R Viant, Gareth J Morgan, Christopher M Bunce, Mark T Drayson

Research output: Contribution to journalArticlepeer-review

34 Citations (Scopus)

Abstract

Biomarker identification is becoming increasingly important for the development of personalized or stratified therapies. Metabolomics yields biomarkers indicative of phenotype that can be used to characterize transitions between health and disease, disease progression and therapeutic responses. The desire to reproducibly detect ever greater numbers of metabolites at ever diminishing levels has naturally nurtured advances in best practice for sample procurement, storage and analysis. Reciprocally, since many of the available extensive clinical archives were established prior to the metabolomics era and were not processed in such an 'ideal' fashion, considerable scepticism has arisen as to their value for metabolomic analysis. Here we have challenged that paradigm.
Original languageEnglish
Pages (from-to)e56422
JournalPLoS ONE
Volume8
Issue number2
DOIs
Publication statusPublished - 2013

Fingerprint

Dive into the research topics of 'Proton NMR-Based Metabolite Analyses of Archived Serial Paired Serum and Urine Samples from Myeloma Patients at Different Stages of Disease Activity Identifies Acetylcarnitine as a Novel Marker of Active Disease'. Together they form a unique fingerprint.

Cite this